Cargando…

Adding GLP-1 Receptor Agonist Therapy to Basal Insulin for Postprandial Glucose Control

Detalles Bibliográficos
Autor principal:	Rhinehart, Andrew S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2015
Materias:	Departments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4398015/ https://www.ncbi.nlm.nih.gov/pubmed/25897187 http://dx.doi.org/10.2337/diaclin.33.2.73

Ejemplares similares

Case Study: Use of GLP-1 Receptor Agonist in a Patient on Intensive Insulin Therapy
por: Wiley, Kenneth Calvin, et al.
Publicado: (2015)

Basal Insulin Use With GLP-1 Receptor Agonists
por: Anderson, Sarah L., et al.
Publicado: (2016)

Combination therapy with GLP-1 receptor agonists and basal insulin: a systematic review of the literature
por: Balena, R, et al.
Publicado: (2013)

Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?
por: Moreira, Rodrigo Oliveira, et al.
Publicado: (2018)

Comparison of Usability, Accuracy, Preference, and Satisfaction Among Three Once-Weekly GLP-1 Receptor Agonist Pen Devices
por: Zhou, Anna Y., et al.
Publicado: (2018)

Impact of Diabetes-Specific Nutritional Formulas versus Oatmeal on Postprandial Glucose, Insulin, GLP-1 and Postprandial Lipidemia
por: Mottalib, Adham, et al.
Publicado: (2016)

Evaluation of postprandial total triglycerides within the TIGG model for characterizing postprandial response of glucose, insulin, and GLP‐1
por: Leohr, Jennifer, et al.
Publicado: (2023)

Is there a justification for classifying GLP-1 receptor agonists as basal and prandial?
por: Miñambres, Inka, et al.
Publicado: (2017)

Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
por: Handelsman, Yehuda, et al.
Publicado: (2019)

Free Versus Fixed-Ratio Combination of Basal Insulin and GLP-1 Receptor Agonists in Type 2 Diabetes Uncontrolled With GLP-1 Receptor Agonists: A Systematic Review and Indirect Treatment Comparison
por: Jung, Han Na, et al.
Publicado: (2022)

Case Study: Remission of Type 2 Diabetes After Outpatient Basal Insulin Therapy
por: Schmidt, Sierra C., et al.
Publicado: (2016)

Correction to: Combining GLP-1 Receptor Agonists and Basal Insulin in Older Adults with Type 2 Diabetes: Focus on Lixisenatide and Insulin Glargine
por: Handelsman, Yehuda, et al.
Publicado: (2019)

A basal-bolus insulin regimen integrated microneedle patch for intraday postprandial glucose control
por: Chen, Bo Zhi, et al.
Publicado: (2020)

Delphi-Based Consensus on Treatment Intensification in Type 2 Diabetes Subjects Failing Basal Insulin Supported Oral Treatment: Focus on Basal Insulin + GLP-1 Receptor Agonist Combination Therapies
por: Fadini, Gian Paolo, et al.
Publicado: (2021)

Glucose lowering and vascular protective effects of cycloset added to GLP‐1 receptor agonists in patients with type 2 diabetes
por: Alatrach, Mariam, et al.
Publicado: (2018)

Successful Resolution of Glucose Toxicity With the Use of Fixed-Ratio Combination Injection of Basal Insulin and Short-Acting Glucagon-Like Peptide 1 (GLP-1) Receptor Agonist
por: Miura, Hiroshi, et al.
Publicado: (2022)

Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes
por: Meiring, Suzanne, et al.
Publicado: (2022)

Implementation of a Multidisciplinary Educational Strategy Promoting Basal-Bolus Insulin Therapy Improves Glycemic Control and Reduces Length of Stay for Inpatients With Diabetes
por: Helmle, Karmon E., et al.
Publicado: (2019)

Therapeutic Options for the Management of Postprandial Glucose in Patients With Type 2 Diabetes on Basal Insulin
por: Hinnen, Debbie A.
Publicado: (2015)

Effects of Teraphy with Basal Insulin Analogues Combined with GLP 1 Analogues and Metformin in the Treatment of Obese Patients with Poorly Regulated Postprandial Glycemia
por: Buturovic, Belma Ascic, et al.
Publicado: (2014)

Acute Administration of the GLP-1 Receptor Agonist Lixisenatide Diminishes Postprandial Insulin Secretion in Healthy Subjects But Not in Type 2 Diabetes, Associated with Slowing of Gastric Emptying
por: Marathe, Chinmay S., et al.
Publicado: (2022)

Favorable Appendicular Skeletal Muscle Mass Changes in Older Patients With Type 2 Diabetes Receiving GLP-1 Receptor Agonist and Basal Insulin Co-Therapy
por: Osaka, Takafumi, et al.
Publicado: (2023)

Switch to Combined GLP1 Receptor Agonist Lixisenatide with Basal Insulin Glargine in Poorly Controlled T2DM Patients with Premixed Insulin Therapy: A Clinical Observation and Pilot Study in Nine Patients
por: Harreiter, Jürgen, et al.
Publicado: (2017)

Regimen comprising GLP-1 receptor agonist and basal insulin can decrease the effect of food on glycemic variability compared to a pre-mixed insulin regimen
por: Lin, Yi-Hsuan, et al.
Publicado: (2022)

Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD
por: Seghieri, Marta, et al.
Publicado: (2018)

Influences of Dietary Added Sugar Consumption on Striatal Food-Cue Reactivity and Postprandial GLP-1 Response
por: Dorton, Hilary M., et al.
Publicado: (2018)

The efficacy and safety of combined GLP-1RA and basal insulin therapy among inadequately controlled T2D with premixed insulin therapy
por: Liu, Jhih-Syuan, et al.
Publicado: (2023)

GLP-1 and GLP-2 as Yin and Yang of Intestinal Lipoprotein Production: Evidence for Predominance of GLP-2–Stimulated Postprandial Lipemia in Normal and Insulin-Resistant States
por: Hein, Gustavo J., et al.
Publicado: (2013)

Fixed versus flexible combination of GLP‐1 receptor agonists with basal insulin in type 2 diabetes: A retrospective multicentre comparative effectiveness study
por: Morieri, Mario Luca, et al.
Publicado: (2019)

Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence
por: Schechter, Meir, et al.
Publicado: (2023)

The Cardiovascular Effects of GLP-1 Receptor Agonists
por: Okerson, Theodore, et al.
Publicado: (2012)

GLP-1 Receptor Agonists and Kidney Protection
por: Greco, Eulalia Valentina, et al.
Publicado: (2019)

The effects of postprandial glucose and insulin levels on postprandial endothelial function in subjects with normal glucose tolerance
por: Suzuki, Kazunari, et al.
Publicado: (2012)

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men
por: Matikainen, Niina, et al.
Publicado: (2016)

Primary-care observational database study of the efficacy of GLP-1 receptor agonists and insulin in the UK
por: Hall, G C, et al.
Publicado: (2013)

Predictors of Responsiveness to GLP-1 Receptor Agonists in Insulin-Treated Patients with Type 2 Diabetes
por: Gavigan, Colleen, et al.
Publicado: (2023)

Attenuated Postprandial GLP-1 Response in Parkinson’s Disease
por: Manfready, Richard A., et al.
Publicado: (2021)

GLP-1 receptor agonists (GLP-1RAs): cardiovascular actions and therapeutic potential
por: Ma, Xiaoxuan, et al.
Publicado: (2021)

Cardiovascular outcomes after initiating GLP-1 receptor agonist or basal insulin for the routine treatment of type 2 diabetes: a region-wide retrospective study
por: Longato, Enrico, et al.
Publicado: (2021)

The GLP-1 receptor agonists exenatide and liraglutide activate Glucose transport by an AMPK-dependent mechanism
por: Andreozzi, Francesco, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_t7rqrjd8ap1k05usfre82p2ili